Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
The programme was conducted as a part of MPMCx, an exclusive management programme for MBBS doctors by IIM-Ahmedabad in collaboration with DailyRounds
Approval to dramatically change CAR-T therapies landscape
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Advances clinical research capabilities with leading regulatory grade registries platform
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Subscribe To Our Newsletter & Stay Updated